ResMed Inc.

RMD Healthcare Medical Instruments & Supplies

ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025. In the quarter to June 2026, revenue grew 8.58%, EPS grew 2.32%, free cash flow fell 21.3% and total debt fell 39.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.

238.97 3.26 −1.35%
Market cap
$34.1B
P/E
22.8×
Fwd P/E
16.6×
Dividend yield
1.03%
F-score
6/9
Altman Z
10.00
Beneish M
−2.59
Dividend safety
96/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
24.27% 25.25% 25.68% 25.41%

+8 more TTM periods

Piotroski F-Score
6 7 7 7
ROA
17.77% 18.59% 19.00% 18.52%
ROIC
21.38% 22.59% 21.42% 21.19%
Return on Tangible Assets
43.38% 46.33% 47.40% 49.01%
Average Days of Receivables
66.90 65.83 66.64 62.99
Free Cash Flow per Share
11.19 11.95 12.18 12.02
Free Cash Flow
1,628.66 1,736.26 1,776.59 1,756.56
Capital Expenditures
(177.17) (153.70) (137.90) (126.81)
Other line items
Cash ROIC
19.26% 20.29% 21.82% 22.20%
Accounts Receivable Turnover
5.72 5.81 5.85 6.12
Accounts Payable Turnover
7.50 8.58 8.97 8.13
Inventory Turnover
2.35 2.40 2.34 2.25
Average Days of Payables
51.21 46.89 43.27 46.39
Days of Inventory on Hand
156.80 156.47 159.34 164.48
Tax Rate
(0.21) (0.20) (0.18) (0.17)
Research and Development Expense of Revenue
6.69% 6.48% 6.46% 6.45%
Selling, General and Administrative Expense of Revenue
19.80% 19.69% 19.45% 19.27%
Share Based Compensation of Revenue
1.85% 1.84% 1.83% 1.76%
Interest Coverage
(37.80) (54.41) (78.10) (119.75)
Operating CF/Net income
1.19 1.24 1.29 1.31
Depreciation/Fixed assets
0.42 0.46 0.44 0.43
Capex/Depreciation
(0.73) (0.58) (0.56) (0.53)
Revenue per Share
38.85 38.10 37.01 35.96
Operating CF per Share
12.41 13.00 13.13 12.88
Capex per Share
(1.22) (1.06) (0.95) (0.87)
Capex to Sales
0.03 0.03 0.03 0.02

Fold the line items

Columns are period end dates